The Relation Between Clinical Features, Angiographic Findings, and the Target Lesion Revascularization Rate in Patients Receiving the Endeavor Zotarolimus-Eluting Stent for Treatment of Native Coronary Artery Disease: An Analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III

American Journal of Cardiology

Volumn 100, Issue 8 SUPPL. 2, 2007, Pages

  Mehta, Rajendra H ^a,b   Leon, Martin B ^c   Sketch Jr , Michael H ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVASCULARIZATION; RISK FACTOR; SAFETY; SURGICAL TECHNIQUE; ZOTAROLIMUS ELUTING STENT;

ANTI-BACTERIAL AGENTS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; REGISTRIES; SIROLIMUS;

EID: 35348892758     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.08.024     Document Type: Article

References (14)

1. Roiron C., Sanchez P., Bouzamondo A., Lechat P., and Montalescot G. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 92 (2006) 641-649
2. Stone G.W., Moses J.W., Ellis S.G., Schofer J., Dawkins K.D., Morice M.C., Colombo A., Schampaert E., Grube E., Kirtane A.J., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
3. Kastrati A., Mehilli J., Pache J., Kaiser C., Valgimigli M., Kelbaek H., Menichelli M., Sabate M., Suttorp M.J., Baumgart D., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
4. Meredith I.T., Ormiston J., Whitbourn R., Kay P., Muller D., Bonan R., Popma J.J., Cutlip D.E., Fitzgerald P., Prpic R., and Kuntz R.E. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary lesions: Endeavor I Trial. EuroIntervention 1 (2005) 157-164
5. Fajadet J., Wijns W., Laarman G.J., Kuck K.H., Ormiston J., Munzel T., Popma J.J., Fitzgerald P.J., Bonan R., and Kuntz R.E. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114 (2006) 798-806
6. Schultheiss H.P., Grube E., Kuck K.H., Suttorp M.J., Heuer H., Bonnier H., Popma J.J., Kuntz R.E., Fadajet J., and Wijns W. Safety of direct stenting with the Endeavor stent: results of the Endeavor II continued access registry. EuroIntervention 3 (2007) 76-81
7. Kandzari D.E., Leon M.B., Popma J.J., Fitzgerald P.J., O'Shaughnessy C., Ball M.W., Turco M., Applegate R.J., Gurbel P.A., Midei M.G., et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 48 (2006) 2440-2447
8. Ako J., Morino Y., Honda Y., Hassan A., Sonoda S., Yock P.G., Leon M.B., Moses J.W., Bonneau H.N., and Fitzgerald P.J. Late incomplete stent apposition after sirolimus-eluting stent implantation a serial intravascular ultrasound analysis. J Am Coll Cardiol 46 (2005) 1002-1005
9. Mehran R., Dangas G., Abizaid A.S., Mintz G.S., Lansky A.J., Satler L.F., Pichard A.D., Kent K.M., Stone G.W., and Leon M.B. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 100 (1999) 1872-1878
10. Cutlip D.E., Chauhan M.S., Baim D.S., Ho K.K.L., Popma J.J., Carrozza J.P., Cohen D.J., and Kuntz R.E. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 40 (2002) 2082-2089
11. Singh M., Gersh B.J., McClelland R.L., Ho K.K., Willerson J.T., Penny W.F., and Holmes Jr. D.R. Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll Cardiol 45 (2005) 198-203
12. Kastrati A., Dibra A., Mehilli J., Mayer S., Pinieck S., Pache J., Dirschinger J., and Schomig A. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 113 (2006) 2293-2300
13. Maeng M., Okkels Jensen L., Rasmussen K., Flensted Lassen J., Romer Krusell L., Thayssen P., and Thuesen L. Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent. Heart 93 (2007) 694-697
14. Hong S.J., Kim M.H., Ahn T.H., Ahn Y.K., Bae J.H., Shim W.J., Ro Y.M., and Lim D.S. Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes. Heart 92 (2006) 1119-1124